Zimmer Biomet has acquired Claymont-based CD Diagnostics
Zimmer and CD Diagnostics initially partnered in 2012 to co-develop and market diagnostics in the field of musculoskeletal healthcare.
As part of the original agreement, Zimmer Biomet successfully marketed the Synovasure Periprosthetic Joint Infection (PJI) test, the first and only test specifically designed and validated for the disease. CD moved operations from Pennsylvania to Delaware a few years ago.
“I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery. As a leader and visionary in musculoskeletal healthcare, Zimmer Biomet is the ideal partner to leverage our expertise in biomarker detection and immunoassay development, and to elevate the value of diagnostics in the treatment of musculoskeletal conditions,” said Dr. Carl Deirmengian, scientific founder of CD Diagnostics.
Richard Birkmeyer, CEO of CD was instrumental in moving the company to Delaware. He formerly headed Strategic Diagnostics, Newark testing company.
CD Diagnostics is focused on analyzing biomarker profiles for various clinical conditions in synovial fluid (a viscous fluid that reduces friction between articular cartilage), and creating diagnostic assays that help physicians make informed decisions that optimize patient care. More than 40,000 samples have been evaluated at CD Diagnostics’ laboratories resulting in more than 15 peer-reviewed publications.